Connect
← Return to Anyone familiar with the clinical trial RMC-6236? Or how to enroll?
Discussion
Anyone familiar with the clinical trial RMC-6236? Or how to enroll?
Pancreatic Cancer | Last Active: May 24 7:16am | Replies (34)Comment receiving replies
I was just denied entry last week into the combined 6236+9805 trial. The focus of this trial was on 9805 (KRAS G12D specific), and apparently the manufacturer is now focused on getting it approved as a second-line therapy. My rejection was because it would have been a third-line therapy for me.
What I've heard from two oncologists is that these drugs do have a good pedigree and track record so far.
My very limited understanding is that 6236 is sort of "broad-spectrum" targeting KRAS G12x ("x" meaning multiple subtypes) whereas 9805 specifically targets KRAS G12D. As a result of its broad targeting, 6236 may cause more side effects than the more narrowly focused 9805.
Good luck to everyone navigating the clinical trial obstacle course!
Replies to "I was just denied entry last week into the combined 6236+9805 trial. The focus of this..."
Connect
Could you try and get into a trial of just the 6236? City of Hope in Irvine (CA) is hoping to get this soon. If you could travel for initial setup you could continue your care back in Florida. Dr.Kasi at Hope will be in charge of that trial. Or there’s the Naliri chemo available which I’ll be starting next week unless radiologist were to set up my SBRT first.